Belite Bio (BLTE) Free Cash Flow (2024 - 2025)
Belite Bio (BLTE) posted quarterly Free Cash Flow of -$10.4 million for Q4 2025, down 114.88% year-over-year from $69.8 million in Q4 2024, and down 114.88% quarter-over-quarter from -$4.8 million in Q4 2024.
Belite Bio (BLTE) Free Cash Flow (2024 - 2025) Analysis & Trends
Belite Bio's Free Cash Flow history runs 2 years deep, the most recent figure standing at -$10.4 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 114.88% year-over-year to -$10.4 million; the TTM figure through Mar 2026 stood at -$10.4 million (down 114.88% YoY), while the FY2025 annual figure was -$37.1 million, down 26.27% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$10.4 million, down from -$4.8 million in the prior quarter.
- The five-year high for Free Cash Flow was -$4.8 million in Q4 2024, with the low at -$10.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.39 Mn |
| Dec 31, 2025 | -10.39 Mn |
| Dec 31, 2024 | -4.83 Mn |
| Dec 31, 2024 | -4.83 Mn |